Comorbidity of heart failure and chronic obstructive pulmonary disease: More than coincidence

Current Heart Failure Reports

Volumn 11, Issue 3, 2014, Pages 337-346

  Güder, Gülmisal ^a,b   Rutten, Frans H ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

COPD; Diagnosis; Heart failure; Management; Pathophysiology; Treatment

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; INTERLEUKIN 6; INTERLEUKIN 8; ROFLUMILAST; SPIRONOLACTONE; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROSIS; BODY PLETHYSMOGRAPHY; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE ASSESSMENT TEST; CLINICAL PRACTICE; COMORBIDITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE CRITERIA; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; HYPOXEMIA; LABORATORY DIAGNOSIS; LEUKOCYTE ADHERENCE; LUNG ARTERY PRESSURE; LUNG CONGESTION; LUNG DIFFUSION; LUNG FUNCTION TEST; LUNG VASCULAR RESISTANCE; MODIFIED BRITISH MEDICAL RESEARCH COUNCIL QUESTIONNAIRE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEW YORK HEART ASSOCIATION CLASS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESIDUAL VOLUME; SMOKING; SPIROMETRY; SPUTUM; TISSUE PRESSURE; TOTAL LUNG CAPACITY; HEALTH; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

COMORBIDITY; GLOBAL HEALTH; HEART FAILURE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84906054509     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-014-0212-x     Document Type: Article

References (111)

1. Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med. 1995;333(23):1547-53.
2. Mulrow CD, Lucey CR, Farnett LE. Discriminating causes of dyspnea through clinical examination. J Gen Intern Med. 1993;8(7):383-92. (Pubitemid 23214016)
3. Tiller D, Russ M, Greiser KH, Nuding S, Ebelt H, Kluttig A, et al. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS One. 2013;8(3):e59225.
4. Mureddu GF, Agabiti N, Rizzello V, Forastiere F, Latini R, Cesaroni G, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail. 2012;14(7):718-29.
5. van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest. 2009;135(2):368-77.
6. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887-94. (Pubitemid 41253302)
7. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264(4):361-9.
8. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130-9.
9. •• McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847. Guidelines on heart failure. Also mentioning COPD as an important comorbidity.
10. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539-50. (Pubitemid 47614269)
11. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523-32. (Pubitemid 44794666)
12. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204-12.
13. Kachel RG. Left ventricular function in chronic obstructive pulmonary disease. Chest. 1978;74(3):286-90. (Pubitemid 9026249)
14. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):20-2. (Pubitemid 40562958)
15. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med Off J Soc Acad Emerg Med. 2003;10(3):198-204. (Pubitemid 36292619)
16. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail. 2006;8(7):706-11. (Pubitemid 44635314)
17. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-65.
18. van Dijk WD, Gupta N, Tan WC, Bourbeau J. Clinical relevance of diagnosing COPD by fixed ratio or lower limit of normal: a systematic review. COPD. 2013;11(1):113-20.
19. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117-22. (Pubitemid 35331867)
20. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J. 2003;22(2):268-73. (Pubitemid 36986996)
21. Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not <70%. Chest. 2007;131(2):349-55. (Pubitemid 46280391)
22. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-68. (Pubitemid 41632054)
23. Steinacher R, Parissis JT, Strohmer B, Eichinger J, Rottlaender D, Hoppe UC, et al. Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure. Clin Res Cardiol Off J German Cardiac Soc. 2012;101(8):637-45.
24. Minasian AG, van den Elshout FJ, Dekhuijzen PN, Vos PJ, Willems FF, van den Bergh PJ, et al. COPD in chronic heart failure: Less common than previously thought? Heart Lung. 2013;42(5):365-71.
25. Olofson J, Bake B, Tengelin MN, Houltz B. COPD 'diagnosis' based on spirometric reference equations. Clin Respir J. 2008;2(4):214-9.
26. • Marks GB. Are reference equations for spirometry an appropriate criterion for diagnosing disease and predicting prognosis? Thorax. 2012;67(1):85-7. Article discussing critically the LLN definition for diagnosing COPD.
27. Wollmer P, Engstrom G. Fixed ratio or lower limit of normal as cut-off value for FEV1/VC: An outcome study. Respir Med. 2013;107(9):1460-2.
28. • Guder G, Brenner S, Angermann CE, Ertl G, Held M, Sachs AP, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res. 2012;13(1):13. Study showing that hyperinflation is useful to improve the diagnosis of COPD.
29. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046-51.
30. Moons KG, Grobbee DE. When should we remain blind and when should our eyes remain open in diagnostic studies? J Clin Epidemiol. 2002;55(7):633-6. (Pubitemid 34831054)
31. Jorge S, Becquemin MH, Delerme S, Bennaceur M, Isnard R, Achkar R, et al. Cardiac asthma in elderly patients: incidence, clinical presentation and outcome. BMC Cardiovasc Disord. 2007;7:16.
32. Assayag P, Benamer H, Aubry P, de Picciotto C, Brochet E, Besse S, et al. Alteration of the alveolar-capillary membrane diffusing capacity in chronic left heart disease. Am J Cardiol. 1998;82(4): 459-64. (Pubitemid 28389944)
33. West JB, Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet. 1992;340(8822): 762-7.
34. Guglin M, Khan H. Pulmonary hypertension in heart failure. J Card Fail. 2010;16(6):461-74.
35. Guder G, Rutten FH, Brenner S, Angermann CE, Berliner D, Ertl G, et al. The impact of heart failure on the classification of COPD severity. J Card Fail. 2012;18(8):637-44.
36. Faggiano P. Abnormalities of pulmonary function in congestive heart failure. Int J Cardiol. 1994;44(1):1-8. (Pubitemid 24110042)
37. Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998;92(12):1321-5. (Pubitemid 29002768)
38. Puri S, Dutka DP, Baker BL, Hughes JM, Cleland JG. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation. 1999;99(9):1190-6. (Pubitemid 29120091)
39. Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med. 1983;143(3):429-33. (Pubitemid 13156428)
40. Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol. 1987;17(2):207-9.
41. Kee K, Naughton MT. Heart failure and the lung. Circ J Off J Jpn Circ Soc. 2010;74(12):2507-16.
42. •• Brenner S, Guder G, Berliner D, Deubner N, Frohlich K, Ertl G, et al. Airway obstruction in systolic heart failure - COPD or congestion? Int J Cardiol 2013. Study that assessed serial spirometry measurements in patients hospitalized for acute decompensated systolic heart failure. It showed that COPD would be overdiagnosed when based on spirometry at the end of hospitalisation as compared to pulmonary function testing six months later when the same HF patients were in a stable phase of their heart failure. Detection of hyperinflation would improve the diagnosis of COPD, and could be performed during hospitalization.
43. Puente-Maestu L, Stringer WW. Hyperinflation and its management in COPD. Int J Chronic Obstructive Pulm Dis. 2006;1(4): 381-400.
44. US Surgeon General: The health consequences of smoking. Chronic obstructive lung disease. A report of the Surgeon General Rockville, Maryland: US Department of Health and Human Services; Public Health Service; 1984 [http://www. surgeongeneral.gov/library/reports/index.html], DHHS (PHS) 84-50205. In.; 1984.
45. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61(11):935-9. (Pubitemid 44787161)
46. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-7. (Pubitemid 38622506)
47. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-26.
48. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996-1002. (Pubitemid 32295654)
49. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711-5. discussion 715-716.
50. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797-9. (Pubitemid 47320803)
51. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen- Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(2):119-29.
52. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514-9. (Pubitemid 36378490)
53. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003;46:5s-13.
54. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):258-66. discussion 290-251.
55. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-95.
56. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-85.
57. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: A study of the general population. COPD. 2010;7(1):5-10.
58. Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD. 2010;7(5):375-82.
59. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28(6):1245-57. (Pubitemid 44883863)
60. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486-91. (Pubitemid 36378485)
61. Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation. 2003;107(11):1460-2. (Pubitemid 36378479)
62. Javed Q, Murtaza I. Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ. 2013;22(5):323-7.
63. Rutten F: Diagnosis and management of heart failure in COPD. Eureopean Respiratory Monogram 2013.
64. Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Eval Manag Chest. 1991;99(3): 715-23.
65. Burghuber O, Bergmann H, Silberbauer K, Hofer R. Right ventricular performance in chronic air flow obstruction. Respiration. 1984;45(2):124-30. (Pubitemid 14198642)
66. Morrison DA, Adcock K, Collins CM, Goldman S, Caldwell JH, Schwarz MI. Right ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease. J Am Coll Cardiol. 1987;9(6):1219-29. (Pubitemid 17083518)
67. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618-24. (Pubitemid 41698701)
68. Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax. 2003;58(7):556-8. (Pubitemid 36808122)
69. Mancini GB, Khalil N. Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin Invest Med. 2005;28(3):118-26. (Pubitemid 40978706)
70. Aronow WS. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest Heart Fail. 2003;9(3):142-7. (Pubitemid 37081527)
71. Guazzi M. Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest. 2003;124(3): 1090-102. (Pubitemid 37123333)
72. Sakamaki F, Satoh T, Nagaya N, Kyotani S, Nakanishi N, Ishida Y. Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest. 1999;116(6):1575-81. (Pubitemid 30012697)
73. Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Pathophysiology. BMJ. 2000;320(7228):167-70.
74. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21): 2837-49. (Pubitemid 40791557)
75. Gosker HR, Lencer NH, Franssen FM, van der Vusse GJ, Wouters EF, Schols AM. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest. 2003;123(5):1416-24. (Pubitemid 36549758)
76. Schols AM. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. Eur Respir J Suppl. 2003;46:81s-6.
77. Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11(12):1182-8.
78. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol. 2008;101(3):353-8. (Pubitemid 351162971)
79. Kwon BJ, Kim DB, Jang SW, Yoo KD, Moon KW, Shim BJ, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail. 2010;12(12):1339-44.
80. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Betablockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880-7.
81. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48.
82. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554-60. (Pubitemid 43866389)
83. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013;34(36):2795-807.
84. •• Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011;57(21):2127-38. Detailed overview of caveats of betablocker and beta-agonist therapy in patients with COPD and heart failure.
85. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780-7.
86. Agostoni P, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail. 2007;9(8):827-33. (Pubitemid 47212829)
87. Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010;12(6):557-65.
88. Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther. 2008;21(1):115-24.
89. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008;38(3):256-62. (Pubitemid 351567693)
90. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.
91. Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA, Hruska N, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J. 2006;27(5):972-9. (Pubitemid 44911111)
92. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, deMolina RM, Nakashima B, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.
93. Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, et al. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J. 2005;26(2):159-64. (Pubitemid 40282784)
94. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123(6):1964-9. (Pubitemid 36706719)
95. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89. (Pubitemid 46294610)
96. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105(4):571-9.
97. Chong J, Karner C, Poole P. Tiotropium versus long-acting betaagonists for stable chronic obstructive pulmonary disease. The Cochrane database of systematic reviews. 2012;9, CD009157.
98. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropiumin chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54.
99. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-103.
100. Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175-85.
101. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-the FDA's conclusions. N Engl J Med. 2010;363(12):1097-9.
102. Karabis A, Lindner L, Mocarski M, Huisman E, Greening A. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, asmaintenance treatment ofmoderate to severe COPD patients: a systematic review and network meta-analysis. International journal of chronic obstructive pulmonary disease. 2013;8:405-23.
103. Reid DJ, Carlson AA. Clinical use of aclidinium in patients with COPD. International journal of chronic obstructive pulmonary disease. 2014;9:369-79.
104. Sharafkhaneh A, Majid H, Gross NJ. Safety and tolerability of inhalational anticholinergics in COPD. Drug, healthcare and patient safety. 2013;5:49-55.
105. Greenberger PA, Cranberg JA, Ganz MA, Hubler GL. A prospective evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable. The American journal of medicine. 1991;91(1):67-73.
106. Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7(1):13-24.
107. White WB, Cooke GE, Kowey PR, Calverley PM, Bredenbroker D, Goehring UM, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144(3):758-65.
108. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (betaagonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3, CD010844.
109. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009;29(8):891-905.
110. Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;4, CD008989.
111. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review andmixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48-56.